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BACKGROUND
OBJECTIVE
CONCLUSION
Parkinson’s disease (PD) patients are affected by 
hypokinetic dysarthria, characterized by 
hypophonia and dysprosody, which worsens 
with disease progression. 
Speech disorders affect nearly 90% of PD 
patients and have a negative impact on quality 
of life. 
Levodopa’s (L-dopa) effect on quality of speech 
is inconclusive; no data are currently available 
for late-stage PD (LSPD). 
To assess the modifications of speech and voice 
in LSPD following an acute L-dopa challenge.
METHODS
LSPD patients (Schwab and England <50/Hoehn 
Yahr >3 [MED ON]) performed several vocal tasks 
before and after an acute L-dopa challenge with a 
supramaximal dose (150%);
The following was assessed during MED OFF 
and MED ON: a) respiratory support for speech 
(time duration of vowel /a/ prolongation); b) 
voice quality (fundamental frequency [F0]); c) 
voice stability (pitch break time, and jitter); d) 
voice variability (standard deviation [SD] of 
speaking F0 during sentences [Sentence F0SD]); 
e) speech rate (syllables/sec); f) motor 
performance (MDS-UPDRS-III) and AIMSm. 
All voice samples were recorded and analyzed 
by a speech and language therapist blinded to 
patients’ therapeutic condition using Praat 5.1 
software. 
RESULTS
Patients
24/27 (14 men) LSPD patients succeeded in performing voice tasks;
Median age and disease duration of patients was 79 [IQR: 71.5-81.7] and 14.5 [IQR: 
11-15.7] years, respectively;
There were no differences in demographic or clinical variables between men and 
women (Table 1). 
Baseline voice and speech characteristics
In MED OFF, respiratory breath support and pitch break time of LSPD patients were 
worse than the normative values of non-parkinsonian (Table 2). 
Mean jitter values were in the normal range (Table 2), although results were 
borderline for men and SD showed a tendency for higher values. 
F0SD  was in the normal range (Table 2).  However, due to the low level of cooperation 
of LSPD patients, we adopted an 8-word (14 syllables) declarative sentence (syntactically 
simple) that in European Portuguese is expected to have a low level of voice variability 
compared to complex sentences or text reading, which are normally used for this task
Voice features and PD severity
A correlation was found between disease duration and voice quality (R=0.51; 
p=0.013) and speech rate (R= -0.55; p=0.008). 
Motor impairment (MDS-UPDRS-III) had a moderate significant correlation with 
respiratory support for speech (R= -0.43; p=0.045) and pitch break time (R= -0.565; 
p=0.006). 
L-dopa challenge test
L-dopa significantly improved MDS-UPDRS-III score (20%; IQR: 11.5%-32%);
Sub-analysis of MDS-UPDRS-III scores for axial signs showed a significant median 
improvement after L-dopa intake for all the sub-items, except speech;
None of voice and speech variables changed significantly after L-dopa intake as 
assessed by automatic analysis (Table 3). 
Equally, separate analysis of non-demented and demented patients showed no 
modification of speech and voice variables following L-dopa intake.
Patients data LSPD (n= 24)
LSPD
MALE (n=14)
LSPD
FEMALE (n=10)
p - value
Age (yrs) 79 [71.5-81.7] 77.5 [70.7-81.2] 79 [73.5-85] ns
Age at disease onset (yrs) 64.5 [54.5-69.5]
62.5 [55-67] 65 [51.5-71.5] ns
Disease duration 14.5 [11-15.7] 13.5 [8.7-17] 15 [11.7-17.2] ns
Education (yrs) 4 [4-11] 4 [4-12] 5 [4-10.5] ns
S&E (ON/OFF) 40/35 [40-40.7 / 22.5-40] 40/30 [40-40/ 40-40] 40/30 [27-50 / 17.5-50] ns
HY (ON/OFF) 4 [2-4] / 4 [2-4.75] 3 [2-4] / 3 [2-4] 4 [4-5] /4 [4-5] ns
PDD (n (%)) 14 (58%) 10 (71%) 4 (40%) ns
MMSE
MMSE (demented/non-demented)
22.5 [21.2-25]
22 [17-23.7] / 25 [23-26.7]
22.5 [22-24.2]
22 [21.7-24.2] / 23 [22.2-25.2]
22.5 [16-27.2]
17 [13-19.5] / 27 [25-28.5]
ns
LEDD (mg) 1037 [902-1272] 1100 [990-1303] 905 [742-1257] ns
MDS-UPDRS-II 31 [27-38] 32 [29.2 – 38.5] 30 [20.5-38] ns
MDS-UPDRS-III (MED ON/MED OFF 50 [40-54]/64 [52-77] 50 [42.5-55.2]/61[53-76] 50 [37.5-62.5] /64 [48-79.5] ns
Axial sign (MED ON/MED OFF 8 [6-13] /10 [7-13] 8 [6-13]/10 [7-13.2] 8 [6.5-12]/ 10 [7-13.5] ns
MDS-UPDRS-IV 4 [2-9.5] 5 [2-8.5] 4 [0-11.2] ns
PD Patients (N=24) Normal value
Respiratory support for 
speech 
Vowel duration (sec)
5.8 [4.4-11.5.8] 22.97 (1.1) ^
Voice stability
Pitch break time (sec)
1.24 [0.2-2.6.1] NA*
Jitter (%) 0.8 [0.5-1.1] ≤ 0.5-1%
Voice variability
F0SD (Hz)
2.4 [1.6-4] 2-4Hz
Voice quality (Hz) - F0 MALE (N=14) FEMALE (N=10) MALE FEMALE
125 [104-152] 202 [160-226.8] 128 (36)** 198 (44)**
LSPD patients (N= 24)
MED OFF MED ON p - value
MDS-UPDRS-III
64 [52-77] 50 [40-54] <0.001
Speech
2 [1-3] 2 [1-3] 0.83
Freezing of gait
3 [1-4] 2 [0-3] <0.05 (0.01)
Postural Stability
3 [2-4] 3 [2-3] <0.05 (0.014)
Gait
3 [2-4] 3 [2-3] <0.05 (0.01)
Axial Signs
10 [7-13] 8 [6-13] <0.05 (0.01)
HY
4 [2-4.75] 4 [2-4] 0.7
mAIMS 0 1 [0-6.75] 0.04
Voice Respiratory support for speech 
Vowel duration (sec)
5.8 [4.4-11.5] 7 [3.6-10.6] 0.6
Voice stability
Pitch break time
1.2  [0.2-2.6] 0.8 [0.07-2.5] 0.9
Jitter 0.8 [0.5-1.1] 0.7 [0.4-1] 0.5
Voice quality
F0
154 [123-209] 162 [147-203] 0.2
Voice variability
SentenceSFoSD
31 [19-51] 29 [20-40] 0.5
Speech rate 5 [3.6-5.6] 5 [4.2-5.7] 0.2
Table 1. Demographic anc clinical features. Values are presented as median [IQR, 25th–75th percentile] if no otherwise specified; ns: not significant.  LEDD: L-dopa equivalent daily dose; 
PDD: Parkinson’s disease with dementia; MMSE: mini mental state examination. S&E: Schwab and England score; HY: Hoehn Yahr Stage; ns: non-significant; P value is the results for male 
vs. female scores’ comparison. 
Table 2 . Baseline speech and voice 
characteristics. Values for LSPD patients 
are presented as median [IQR, 25th–75th 
percentile]. Values for healthy subjects are 
presented as mean (SD), as reported in 
literature (Maslan J. et al., 2011; Barkana
BD & Zhou JA, 2015, Colton & Casper, 
1996; Titze IR, 1993). F0: fundamental 
frequency; F0SD: fundamental frequency 
standard deviation; NA*: not available 
(healthy voices should have no trouble in 
maintaining voicing during a sustained 
vowel. Thus is 0% of voice breaks. No 
standard values are available). ^: normal 
value for vowel duration are referred to a 
healthy population aged between 71 and 
80 years old. **: normal value for voice 
quality are referred to a healthy population 
aged between 55 and 80 years old.
Table 3. L-dopa challenge test. 
Values are presented as median [IQR, 
25th–75th percentile]. Statistical 
significant results are in bold. Axial 
Signs: sum of item 3.1, 3.10-3.12 of 
the MDS-UPDRS-III. P – value is the 
results of MED OFF versus MED ON 
scores. mAIMS: Modified Abnormal 
Involuntary Movement Scale. 
 Speech is severely affected among LSPD patients. 
 No effect of L-dopa was found on speech and voice by means of both automated 
analysis and clinical evaluation, although patients had a moderate positive motor 
response, even present for some axial signs, with the exception of speech. 
 Our findings highlight the need to assess the efficacy and applicability of alternative 
non-dopaminergic/non-pharmacologic treatments to specifically target and improve 
communication of LSPD patients.
